A-Alpha Bio
Key Highlights
- A-Alpha Bio's unique combination of synthetic biology and machine learning for protein-protein interaction research.
- The company's proprietary platforms, AlphaSeq and AlphaBind, provide both experimental and computational insights into protein interactions.
- A-Alpha Bio's partnerships with leading pharmaceutical companies to inform the discovery and development of novel therapeutics.
- The company's foundation at the University of Washington's Institute for Protein Design and Center for Synthetic Biology, highlighting its strong academic roots.
- A-Alpha Bio's focus on accelerating the development of new therapeutics through comprehensive protein interaction research.
About A-Alpha Bio
A-Alpha Bio is a biotechnology company based in Seattle, founded in 2017, that specializes in using synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Their platforms, AlphaSeq and AlphaBind, enable the rapid and quantitative measurement of millions of protein-protein binding affinities and predict binding strength from sequence, respectively. These tools are used for in-house therapeutic programs and in partnership with leading pharmaceutical companies to inform the discovery and development of novel therapeutics.
A-Alpha Bio leverages its proprietary platforms to provide insights into protein interactions, which are crucial for drug discovery and development. The company's approach combines experimental data with computational predictions, offering a comprehensive view of protein interactions that can accelerate the development of new therapeutics.
Founded at the University of Washington's Institute for Protein Design and Center for Synthetic Biology, A-Alpha Bio has established itself as a leader in the biotechnology sector, particularly in the field of protein-protein interaction research. Their innovative use of synthetic biology and machine learning sets them apart in the competitive landscape of biotechnology.
Technology Stack
- AlphaSeq
- Machine Learning
- Synthetic Biology
Why Contact A-Alpha Bio?
B2B professionals would contact A-Alpha Bio for its cutting-edge technology in protein-protein interaction research and its potential to accelerate drug discovery and development. The company's partnerships with leading pharmaceutical companies also present opportunities for collaboration and innovation in the biotechnology sector.
Who Should Contact A-Alpha Bio for Business?
Sales teams selling biotechnology services, recruiters seeking roles in synthetic biology and machine learning, and partners offering computational biology capabilities should reach out to A-Alpha Bio.
Categories
- Biotechnology
- Synthetic Biology
- Machine Learning
- Protein-Protein Interactions
- Drug Discovery
- Therapeutics Development
- AlphaSeq
- AlphaBind
- Computational Biology
- Pharmaceutical Partnerships
More Biotechnology Companies
Frequently Asked Questions
- What does A-Alpha Bio do?
- A-Alpha Bio is a biotechnology company that utilizes synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions through its experimental platform, AlphaSeq.
- How many employees does A-Alpha Bio have?
- A-Alpha Bio has approximately 52 employees.
- Where is A-Alpha Bio headquartered?
- A-Alpha Bio is headquartered in Seattle, Washington, at 4000 Mason Rd, Suite 304, United States.
- What industry is A-Alpha Bio in?
- A-Alpha Bio operates in Biotechnology, Pharmaceutical Research, Synthetic Biology.
- When was A-Alpha Bio founded?
- A-Alpha Bio was founded in 2017.
- Is A-Alpha Bio still active?
- Yes, A-Alpha Bio was verified as an active company on February 2, 2026. Data Surfer regularly validates company information to ensure accuracy.
- How do I sell to A-Alpha Bio?
- Research A-Alpha Bio's priorities and goals, identify the right decision makers and champions, monitor for buying signals, and reach out at the right time with verified contact details. Learn how Data Surfer helps.
Ready to Sell to A-Alpha Bio?
Get qualified leads in 10 minutes. Research prospects, find decision makers, and monitor for the perfect moment to reach out.
Last verified: February 2, 2026
Backed by startup programs from
Connect with A-Alpha Bio